Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma
SK Lau, S Prakash, SA Geller, R Alsabeh - Human pathology, 2002 - Elsevier
Distinguishing hepatocellular carcinoma (HCC) from cholangiocarcinoma (CC) and
metastatic adenocarcinoma (MA) involving the liver can be problematic, often requiring the
use of immunohistochemistry to facilitate diagnosis. Hep Par 1, a monoclonal antibody with
expression confined primarily to benign and malignant hepatocytes, has recently become
commercially available. We evaluated Hep Par 1 along with other immunohistochemical
markers used to differentiate HCC, CC, and MA, including AE1/AE3, CAM 5.2, B72. 3 …
metastatic adenocarcinoma (MA) involving the liver can be problematic, often requiring the
use of immunohistochemistry to facilitate diagnosis. Hep Par 1, a monoclonal antibody with
expression confined primarily to benign and malignant hepatocytes, has recently become
commercially available. We evaluated Hep Par 1 along with other immunohistochemical
markers used to differentiate HCC, CC, and MA, including AE1/AE3, CAM 5.2, B72. 3 …
